Core Viewpoint - The company, Haijia Medical, announced a share buyback program due to its stock price not reflecting its intrinsic value or business prospects, committing to repurchase shares for at least RMB 300 million [1]. Group 1: Share Buyback Announcement - On December 15, Haijia Medical disclosed its intention to buy back shares, stating that the current trading price does not reflect its intrinsic value [1]. - The company executed its first buyback on December 17, purchasing approximately 493,800 shares for about HKD 6.0098 million [1]. Group 2: Market Performance Analysis - On December 12, Haijia Medical's stock hit a year-low of HKD 11.33, indicating a downward trend away from the 5-day moving average [3]. - Since August 1, the stock has been in a downtrend, with a significant drop following a profit warning, leading to low trading volumes [3][5]. - The stock's highest price on December 12 was HKD 11.61, which was below the lower Bollinger Band of HKD 11.64, indicating an oversold condition [3]. Group 3: Trading Volume and Market Sentiment - Following the buyback announcement, trading volume increased significantly, with a notable rise in daily average volume, indicating a shift in market sentiment [5][8]. - On December 16, the stock rose by 3.27% but showed signs of selling pressure, with trading volume increasing by 152.05% compared to the previous day [5][6]. Group 4: Financial Performance and Valuation - Haijia Medical's mid-year report indicated a decline in revenue for inpatient and outpatient services, with inpatient revenue at RMB 1.22 billion (down 18.4% year-on-year) and outpatient revenue at RMB 722 million (down 11.2% year-on-year) [9]. - The company reported stable patient visits at 2.2 million, suggesting demand for its services remains unaffected despite revenue declines [9]. - The company is optimizing capital allocation, with a decrease in capital expenditures to RMB 242 million, down 28.5% year-on-year, and plans to focus on acquisitions rather than new hospital constructions [10]. Group 5: Industry Valuation Context - Haijia Medical's price-to-earnings (PE) ratio stands at 15.71, significantly lower than the industry average of 17, indicating a potential undervaluation compared to peers [11].
高效执行3亿元回购想提振市场信心，海吉亚医疗(06078)还没到反弹时刻？